Expanding Vaccine Portfolio Dynavax is actively developing new vaccine formulations such as the four-dose HEPLISAV-B regimen for adults on hemodialysis and a novel shingles vaccine candidate. These advancements present opportunities to collaborate with healthcare providers and supply chain partners to enhance vaccine distribution channels.

Strategic Manufacturing Partnerships The company's recent partnership with West Pharmaceutical Services for syringe stoppers indicates an openness to collaborate with ancillary vaccine suppliers. This opens avenues for sales of high-quality components, manufacturing services, and supply chain solutions to support their expanding product line.

Research and Clinical Trials Dynavax's ongoing clinical trials and recent top-line data presentations suggest potential demand for advanced research tools, clinical testing services, and biotech equipment. Engaging with their research teams could unlock opportunities in laboratory supplies and trial-related services.

Market Expansion Opportunities With products approved in the US, EU, and UK, and a focus on infectious disease vaccines, Dynavax is positioned for international growth. Targeted outreach to regional distributors, regulatory consultants, and healthcare providers can help accelerate market penetration and sales expansion.

Financial Growth and Investment Having secured substantial funding and generating significant revenue, Dynavax represents a financially stable partner with growth potential. This makes them a strong candidate for strategic collaborations, co-marketing arrangements, and long-term supply agreements across their vaccine portfolio.